EntryPoint Capital LLC Makes New Investment in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

EntryPoint Capital LLC purchased a new stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 4th quarter, Holdings Channel reports. The firm purchased 26,450 shares of the company’s stock, valued at approximately $221,000.

Other hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Zevra Therapeutics during the 4th quarter valued at $94,000. XTX Topco Ltd acquired a new stake in shares of Zevra Therapeutics during the third quarter valued at $94,000. Intech Investment Management LLC acquired a new stake in shares of Zevra Therapeutics during the third quarter valued at $95,000. Virtu Financial LLC purchased a new stake in Zevra Therapeutics during the 3rd quarter worth about $127,000. Finally, Quantbot Technologies LP acquired a new position in Zevra Therapeutics in the 3rd quarter valued at about $140,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Down 1.4 %

ZVRA stock opened at $7.85 on Friday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market cap of $424.81 million, a price-to-earnings ratio of -3.98 and a beta of 1.98. The business has a fifty day simple moving average of $7.90 and a 200-day simple moving average of $8.20. Zevra Therapeutics, Inc. has a 52 week low of $4.20 and a 52 week high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million. On average, equities research analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, March 19th. The stock was bought at an average price of $7.96 per share, with a total value of $79,600.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $318,400. The trade was a 33.33 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. The trade was a 17.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,773 shares of company stock worth $674,176. Company insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ZVRA. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday, March 13th. Canaccord Genuity Group lifted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim lifted their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Finally, JMP Securities set a $18.00 target price on Zevra Therapeutics in a research note on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zevra Therapeutics has an average rating of “Buy” and an average target price of $22.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.